Skip to content

Mobile Cardiac Telemetry (MCT) Study

Mobile Cardiac Telemetry (MCT) Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07158333
Enrollment
15
Registered
2025-09-05
Start date
2025-08-05
Completion date
2025-09-12
Last updated
2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This study will be a single center, single arm, open-label, prospective study to evaluate adhesive performance of the Bardy Diagnostics' (BardyDx) MCT Patch up to 30 days of wear.

Interventions

DEVICEMobile Cardiac Telemetry (MCT System)

MCT System without data transmission

Sponsors

Baxter Healthcare Corporation
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Each subject must meet the following criteria to be enrolled in this study: 1. Subject is ≥18 years of age. 2. Completes the consent process as required. 3. Subject can speak and read English fluently. 4. Subject is willing to allow shaving of device application area, as required. 5. Subject is willing and able to take photos of the application area before, during, and immediately after wear of each Adhesive Patch

Exclusion criteria

1. Unable to comply with the study protocol and instructions for wearing the MCT Patch for up to 30 days. 2. Geographically located such that they cannot have the initial MCT Patch placed by PI or designee. 3. Any breached or compromised skin, skin rash, irritation or infection over the sternum (prior to the initial application) as reported by the subject and/or observed by the PI during initial application. 4. Had any sternal incision or wound within 3 months prior to the date of enrolment. 5. Subjects with sensitive skin or known skin conditions, including known allergies. 6. Subjects with scheduled cardioversion during the data collection period. 7. Subjects with a scheduled electronic imaging (including magnetic resonance imaging) during the data collection period. 8. Subject has known cardiac arrhythmia conditions (Note: The PI will assess the subject during initial screening. If an arrhythmia is discovered during the subject will be deemed ineligible for participation in the study).

Design outcomes

Primary

MeasureTime frameDescription
Cumulative wear time30 daysas measured by ECG readability sufficient for identification of the P and QRS waves; the total readable duration summed from each patch, measured from the start of the first day to the end

Secondary

MeasureTime frameDescription
Subject Self-Reported Log & Subject Survey of the MCT Patch after 30 days30 daysskin and adhesive comfort, and device stability and skin contact
Adverse events of relevance, including potential skin damage due to repeated removal and reapplication of the MCT Patch as determined by Investigator/designee from subject assessments including Subject Logs, Subject Surveys and photos.From enrollment to end of study at 30 days.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026